Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
National
Tom Murphy

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Earns Eli Lilly - (Copyright 2017 The Associated Press. All rights reserved.)

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 billion.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.